Beone Medicines Ltd. (ONC) Stock Price & Analysis
Beone Medicines Ltd. (ONC) fell 0.97% to USD 268.17 as of June 9, 2026 at 23:52 UTC, according to Nexqual real-time market data.
ONC last closed at USD 270.8; the session ranged USD 265.32–271.4 on volume of 501,834 shares. Market capitalization is $27.82B, with a 52-week range of USD 239.25–385.22 (NMS). Source: Nexqual, June 9, 2026 at 23:52 UTC.
Key Statistics (as of June 9, 2026 at 23:52 UTC)
| Price | USD 268.17 |
|---|---|
| Change | ▼ 0.97% (down) |
| Previous Close | USD 270.8 |
| Open | USD 267.66 |
| Day Range | USD 265.32 – 271.4 |
| 52-Week Range | USD 239.25 – 385.22 |
| Volume | 501,834 shares |
| Market Cap | $27.82B |
| Exchange | NMS |
Technical Analysis (ONC)
Nexqual's technical model rates ONC "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:52 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.86 (oversold) |
| vs SMA50 | Below (USD 300.84) |
| MACD | -8.99 (negative) |
Analyst Ratings (ONC)
Wall Street analysts rate ONC "Strong Buy" based on 28 analysts, with a mean price target of USD 411.91 (range USD 333–501.3), per Nexqual as of June 9, 2026 at 23:52 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 28 |
| Mean Target | USD 411.91 |
| High Target | USD 501.3 |
| Low Target | USD 333 |
| Buy / Hold / Sell | 27 / 1 / 0 |
Earnings (ONC)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 1.59 |
| Revenue Estimate | $1.59B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.96 vs est 0.81 ▲ beat |
| 2025-12-31 | USD 0.58 vs est 1.3 ▼ miss |
| 2025-09-30 | USD 1.09 vs est 0.86 ▲ beat |
| 2025-06-30 | USD 0.84 vs est 0.26 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Financials & Fundamentals (ONC)
| Total Revenue | $5.74B |
|---|---|
| Revenue Growth (YoY) | +35.50% |
| Gross Margin | +88.31% |
| Operating Margin | +16.51% |
| Profit Margin | +8.94% |
| ROE | +12.42% |
| Debt / Equity | 24.14 |
| Current Ratio | 3.64 |
| Total Cash | $4.79B |
| Total Debt | $1.15B |
| Free Cash Flow | $917.30M |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Financial Health Score (ONC)
Nexqual rates Beone Medicines Ltd.'s overall financial health "Strong" across five dimensions, as of June 9, 2026 at 23:52 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 88%, operating 17% |
| Balance Sheet | Strong — $4.79B cash vs $1.15B debt, net cash position |
| Cash Flow | Strong — FCF $917M, 17% margin |
| Efficiency | Mixed — ROE 12%, ROA 6.0% |
Ownership (ONC)
| Insider Ownership | +17.29% |
|---|---|
| Institutional Ownership | +32.95% |
| Shares Outstanding | 94.90M |
| Float | 78.05M |
| Short % of Float | +1.47% |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Leadership (ONC)
Beone Medicines Ltd. is led by John V. Oyler (age 57), Co-Founder, Executive Chairman & CEO, per Nexqual as of June 9, 2026 at 23:52 UTC.
| Co-Founder, Executive Chairman & CEO | John V. Oyler (age 57) |
|---|---|
| President and Global Head of Research & Development | Wang Lai (age 47) |
| Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Xiaodong Wang (age 62) |
| Chief Financial Officer | Aaron Rosenberg (age 48) |
| Chief Technology Officer | Marcello Damiani (age 55) |
Major Backers & Investors (ONC)
Notable institutional backers of Beone Medicines Ltd. include Baker Bros. Advisors, LP, Primecap Management Company, Capital International Investors, according to Nexqual as of June 9, 2026 at 23:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 8.02% |
| Primecap Management Company | 4.53% |
| Capital International Investors | 3.79% |
| FMR, LLC | 3.37% |
| NEW PERSPECTIVE FUND | 2.43% |
| Capital Group | 1.48% |
| Fidelity | 1.21% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.18% |
| BlackRock | 1.08% |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
From Beone Medicines Ltd.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
- The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
- The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
| ARGX | argenx SE | USD 884 | ▼ 0.82% |
| CGON | CG Oncology, Inc. | USD 56.67 | ▲ 5.49% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 95.48 | ▲ 2.14% |
| RVMD | Revolution Medicines, Inc. | USD 149.55 | ▲ 0.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:52 UTC. This page is informational and not investment advice.